JLPC has obtained the drug registration certificate for Famotidine Injection
JLPC recently obtained the "Drug Registration Certificate" for Famotidine Injection approved by the National Medical Products Administration. This medication treats by inhibiting gastric acid secretion and belongs to the class of histamine H2 receptor antagonists. The acquisition of this certificate enriches the company's product line and enhances market competitiveness, but it is expected to have no significant impact on recent operating performance
According to the Zhitong Finance APP, JLPC (600513.SH) announced that the company recently received the Drug Registration Certificate for Famotidine Injection issued by the National Medical Products Administration (referred to as "NMPA"). Famotidine Injection is a medication that exerts its therapeutic effect by inhibiting gastric acid secretion and belongs to the class of histamine H2 receptor antagonists.
The acquisition of the Drug Registration Certificate for Famotidine Injection further enriches the company's product line and helps enhance the market competitiveness of the company's products. The receipt of the above Drug Registration Certificate is expected to have no significant impact on the company's recent operating performance
